Coherus BioSciences Inc. - CHRS Enterprise Value-to-Sales Ratio

Official company branding of coherus.com (CHRS)

Coherus Biosciences' transition toward developing unique oncology drugs opens growth opportunities, which is reflected in the EV/Revenue ratio from GURU.Markets via the 852.91 metric, capturing this status. Stable demand for cancer therapy provides the business with macro resilience. However, cash flow volatility and pricing pressure in the US create certain challenges for the predictability of final earnings.

Coherus (CHRS): Company Value to Revenue from 11/23/2025 to 11/20/2026

Coherus BioSciences, Inc. - analytical breakdowns and key metrics (CHRS)

- price and consensus price forecast:
- cash balance and cash flow data:
Fundamental company valuation:CHRS, Coherus Biosciences
Manufactured products of Coherus BioSciences

Institutional capital utilizes this metric to determine the fair market value of Coherus Biosciences (CHRS). The calculation combines market capitalization and net debt, comparing the resulting sum to annual sales volume. The price-to-sales ratio trend reflects the degree of business overvaluation relative to actual cash flows. Effective commercialization of drugs by the industry's top experts should maintain a stable trend for this indicator. Low values confirm the fundamental resilience of the asset.